LianBio (LIAN) News Today $0.29 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period China's Zeekr prices US IPO at top of range to raise $441 millionMay 10, 2024 | msn.comExclusive-China's Zeekr prices US IPO at top of range to raise $441 million, source saysMay 9, 2024 | msn.comWhy Is LianBio (LIAN) Stock Moving Today?March 15, 2024 | investorplace.comLianBio (NASDAQ:LIAN) Short Interest Down 33.5% in FebruaryLianBio (NASDAQ:LIAN - Get Free Report) was the target of a significant drop in short interest during the month of February. As of February 29th, there was short interest totalling 378,100 shares, a drop of 33.5% from the February 14th total of 568,800 shares. Based on an average trading volume of 523,800 shares, the short-interest ratio is currently 0.7 days. Approximately 0.4% of the shares of the stock are short sold.March 15, 2024 | marketbeat.comLianBio (NASDAQ:LIAN) Sets New 52-Week High at $4.98LianBio (NASDAQ:LIAN) Hits New 52-Week High at $4.98March 14, 2024 | marketbeat.comLianBio (NASDAQ:LIAN) Sets New 52-Week High at $4.96LianBio (NASDAQ:LIAN) Reaches New 52-Week High at $4.96March 8, 2024 | marketbeat.comLianBio (NASDAQ:LIAN) Sets New 12-Month High at $4.88LianBio (NASDAQ:LIAN) Sets New 1-Year High at $4.88March 1, 2024 | marketbeat.comLianBio Announces Voluntarily Delisting from NasdaqFebruary 28, 2024 | globenewswire.comWith No Cure In Sight, Drugs Firm LianBio Begins Exit StrategyFebruary 23, 2024 | seekingalpha.comLianBio (NASDAQ:LIAN) Sees Strong Trading VolumeLianBio (NASDAQ:LIAN) Sees Strong Trading VolumeFebruary 14, 2024 | marketbeat.comLianBio Announces Wind Down Of Operations, Workforce Reduction; Stock Up In Pre-MarketFebruary 13, 2024 | markets.businessinsider.comLianBio (NASDAQ:LIAN) Sets New 52-Week High at $4.88LianBio (NASDAQ:LIAN) Reaches New 12-Month High at $4.88February 13, 2024 | marketbeat.comLianBio to Wind Down Operations, Declares Special DividendFebruary 13, 2024 | marketwatch.comLianBio Shares Gain After Co Announces Plans to Wind DownFebruary 13, 2024 | marketwatch.comLianBio Announces Completion of Strategic ReviewFebruary 13, 2024 | finance.yahoo.com131,641 Shares in LianBio (NASDAQ:LIAN) Acquired by Landscape Capital Management L.L.C.Landscape Capital Management L.L.C. purchased a new stake in shares of LianBio (NASDAQ:LIAN - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 131,641 shares of the coFebruary 8, 2024 | marketbeat.comShort Interest in LianBio (NASDAQ:LIAN) Rises By 19.6%LianBio (NASDAQ:LIAN - Get Free Report) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 1,280,000 shares, an increase of 19.6% from the December 15th total of 1,070,000 shares. Based on an average trading volume of 2,500,000 shares, the days-to-cover ratio is currently 0.5 days. Currently, 1.2% of the shares of the stock are sold short.January 14, 2024 | marketbeat.comB of A Securities Downgrades LianBio: Here's What You Need To KnowJanuary 3, 2024 | markets.businessinsider.comLianBio (NASDAQ:LIAN) Lowered to Underperform at Bank of AmericaBank of America lowered shares of LianBio from a "buy" rating to an "underperform" rating and reduced their price target for the company from $5.00 to $3.00 in a research report on Wednesday.January 3, 2024 | marketbeat.comNanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian MarketsDecember 26, 2023 | markets.businessinsider.comLianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian MarketsDecember 26, 2023 | finance.yahoo.comLianBio (NASDAQ:LIAN) Lowered to Hold at Jefferies Financial GroupJefferies Financial Group lowered LianBio from a "buy" rating to a "hold" rating and lowered their price target for the company from $7.00 to $4.00 in a research report on Friday.December 22, 2023 | marketbeat.comInterest Is Growing for Smaller, More Speculative NamesDecember 20, 2023 | realmoney.thestreet.comLianBio Announces Departure of Chief Financial OfficerDecember 20, 2023 | finance.yahoo.comLianBio Names Stone as Interim CEO as Wang ResignsDecember 19, 2023 | marketwatch.comLianBio Announces Departure of Chief Executive OfficerDecember 19, 2023 | finance.yahoo.comLianBio’s Board of Directors Unanimously Determines not to Pursue Unsolicited Proposal from Concentra BiosciencesDecember 6, 2023 | finance.yahoo.comLianBio Confirms Receipt of Unsolicited Proposal from Concentra BiosciencesDecember 1, 2023 | finance.yahoo.comLianBio (LIAN) Reports Q3 2023 Financial Results: Strategic Review in Progress Amid Clinical ...November 14, 2023 | finance.yahoo.comLianBio Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 13, 2023 | finance.yahoo.comAll You Need to Know About LianBio Sponsored ADR (LIAN) Rating Upgrade to Strong BuyNovember 8, 2023 | finance.yahoo.comLianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex BlepharitisOctober 30, 2023 | finance.yahoo.comWhy LianBio Stock Is Shooting Through the Roof This WeekOctober 27, 2023 | fool.comLianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023October 25, 2023 | finance.yahoo.comRaymond James Maintains Outperform Rating for LianBio: Here's What You Need To KnowOctober 25, 2023 | markets.businessinsider.comLianBio Reaches Agreement With Bristol Myers Squibb For Mavacamten; Stock UpOctober 24, 2023 | markets.businessinsider.comLianBio Shares Soar Premarket on Strategic Review, End of Bristol PactOctober 24, 2023 | marketwatch.comWe're Not Very Worried About LianBio's (NASDAQ:LIAN) Cash Burn RateSeptember 8, 2023 | finance.yahoo.comLianBio Announces Results from Phase 3 EXPLORER-CN Trial of Mavacamten Presented at the European Society of Cardiology Congress and Simultaneous Publication in JAMA CardiologyAugust 28, 2023 | finance.yahoo.comLianBio Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 14, 2023 | finance.yahoo.comLianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR MutationsAugust 3, 2023 | finance.yahoo.comInstitutions own 21% of LianBio (NASDAQ:LIAN) shares but private equity firms control 54% of the companyJuly 29, 2023 | finance.yahoo.comLianBio Partner Tarsus Pharmaceuticals Announces U.S. FDA Approval of XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex BlepharitisJuly 27, 2023 | finance.yahoo.comLianBio Partner NANOBIOTIX Enters into License Agreement with Janssen for Radioenhancer NBTXR3, with LianBio Retaining Development and Commercialization Rights in Greater China, South Korea, Singapore and ThailandJuly 18, 2023 | finance.yahoo.comLianBio Announces Phase 3 EXPLORER-CN Data Accepted for Late-Breaking Presentation at the European Society of Cardiology Congress 2023July 17, 2023 | finance.yahoo.comLianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR MutationsJuly 12, 2023 | finance.yahoo.comLianBio (NASDAQ:LIAN) Short Interest Up 193.4% in JuneLianBio (NASDAQ:LIAN - Free Report) saw a large increase in short interest in June. As of June 15th, there was short interest totalling 225,600 shares, an increase of 193.4% from the May 31st total of 76,900 shares. Approximately 0.2% of the shares of the stock are short sold. Based on an average trading volume of 207,600 shares, the days-to-cover ratio is currently 1.1 days.June 30, 2023 | marketbeat.comLianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in SingaporeJune 26, 2023 | finance.yahoo.com2 Stocks I'm Watching in a Market Supported by FOMO and Short SqueezesJune 12, 2023 | realmoney.thestreet.comLianBio Completes Enrollment in Pivotal Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex BlepharitisJune 8, 2023 | finance.yahoo.com Get LianBio News Delivered to You Automatically Sign up to receive the latest news and ratings for LIAN and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump won. Buy this coin now. (Ad)Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher. This could be his favorite coin. LIAN Media Mentions By Week LIAN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LIAN News Sentiment▼0.000.47▲Average Medical News Sentiment LIAN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LIAN Articles This Week▼01▲LIAN Articles Average Week Get LianBio News Delivered to You Automatically Sign up to receive the latest news and ratings for LIAN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OMGA News AFMD News VTYX News IFRX News RPTX News CRDL News OTLK News PLX News CNTX News AVTX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LIAN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LianBio Please log in to your account or sign up in order to add this asset to your watchlist. Share LianBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
